Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Randomized, Double-blind, Placebo-controlled, Superiority, Phase IV Trial to Evaluate the Efficacy and Safety of Entelon 50mg Compared to Placebo in Patients With Non-Proliferative Diabetic Retinopathy

NCT05358080 is registered in ClinicalTrials.gov with Hanlim Pharm. Co., Ltd. as lead sponsor.

NCT NCT05358080
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05358080 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Randomized, Double-blind, Placebo-controlled, Superiority, Phase IV Trial to Evaluate the Efficacy and Safety of Entelon 50mg Compared to Placebo in Patients With Non-Proliferative Diabetic Retinopathy
Lead sponsor
Hanlim Pharm. Co., Ltd.
Phase
Phase 4
Overall status
Unknown status
Start date
May 27, 2022
Completion date
December 16, 2024
Enrollment
396 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non proliferative diabetic retinopathy